Human in vivo regional intestinal permeability: Importance for pharmaceutical drug development

Molecular Pharmaceutics

Volumn 11, Issue 1, 2014, Pages 12-23

  Lennernäs, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

bioavailability; Biopharmaceutics Classification System; Biopharmaceutics Drug Disposition Classification System; drug absorption; human intestinal permeability; intestinal perfusion; intestinal transporters; pharmacokinetics

Indexed keywords

AMILORIDE; AMOXICILLIN; ATENOLOL; CARBAMAZEPINE; CEFALEXIN; CIMETIDINE; CYCLOSPORIN; DESIPRAMINE; ENALAPRIL MALEATE; ENALAPRILAT; FEXOFENADINE; FLUINDOSTATIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INOGATRAN; ISOTRETINOIN; KETOPROFEN; LEVODOPA; LISINOPRIL; LOSARTAN; METHYLDOPA; METOPROLOL; NAPROXEN; PHENAZONE; PIROXICAM; PROPRANOLOL; RANITIDINE; TERBUTALINE; UNINDEXED DRUG; VALACICLOVIR;

BLOOD LEVEL; COLON ABSORPTION; COMPUTER MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; FIRST PASS EFFECT; GASTROINTESTINAL ABSORPTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRADUODENAL DRUG ADMINISTRATION; JEJUNUM; PRIORITY JOURNAL; REVIEW; STOMACH ABSORPTION;

BIOLOGICAL AVAILABILITY; BIOPHARMACEUTICS; CELL MEMBRANE PERMEABILITY; COMPUTER SIMULATION; DRUG DESIGN; HUMANS; INTESTINAL ABSORPTION; INTESTINES; PHARMACEUTICAL PREPARATIONS;

EID: 84891767016     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4003392     Document Type: Review

References (120)

1. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 1995, 12, 413-420
2. Lennernas, H.; Abrahamsson, B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension J. Pharm. Pharmacol. 2005, 57, 273-285
3. Dahan, A.; Lennernas, H.; Amidon, G. L. The fraction dose absorbed, in humans, and high jejunal human permeability relationship Mol. Pharmaceutics 2012, 9, 1847-1851
4. Amidon, K. S.; Langguth, P.; Lennernas, H.; Yu, L.; Amidon, G. L. Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy Clin. Pharmacol. Ther. 2011, 90, 467-470
5. Ungell, A. L.; Nylander, S.; Bergstrand, S.; Sjoberg, A.; Lennernas, H. Membrane transport of drugs in different regions of the intestinal tract of the rat J. Pharm. Sci. 1998, 87, 360-366
6. Wu, C. Y.; Benet, L. Z. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm. Res. 2005, 22, 11-23
7. Benet, L. Z.; Broccatelli, F.; Oprea, T. I. BDDCS applied to over 900 drugs AAPS J. 2011, 13, 519-547
8. Chen, M. L.; Amidon, G. L.; Benet, L. Z.; Lennernas, H.; Yu, L. X. The BCS, BDDCS, and regulatory guidances Pharm. Res. 2011, 28, 1774-1778
9. Benet, L. Z. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development J. Pharm. Sci. 2013, 102, 34-42
10. Smith, D. A. Evolution of ADME Science: Where Else Can Modeling and Simulation Contribute? Mol. Pharmaceutics 2013, 10, 1162-1170
11. Menard, S.; Cerf-Bensussan, N.; Heyman, M. Multiple facets of intestinal permeability and epithelial handling of dietary antigens Mucosal. Immunol. 2010, 3, 247-259
12. Tannergren, C.; Bergendal, A.; Lennernas, H.; Abrahamsson, B. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment Mol. Pharmaceutics 2009, 6, 60-73
13. Sjoberg, A.; Lutz, M.; Tannergren, C.; Wingolf, C.; Borde, A.; Ungell, A. L. Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique Eur. J. Pharm. Sci. 2013, 48, 166-180
14. Niu, X.; de Graaf, I. A.; Groothuis, G. M. Evaluation of the intestinal toxicity and transport of xenobiotics utilizing precision-cut slices Xenobiotica 2013, 43, 73-83
15. Yoshida, K.; Maeda, K.; Sugiyama, Y. Transporter-mediated drug - drug interactions involving OATP substrates: predictions based on in vitro inhibition studies Clin. Pharmacol. Ther. 2012, 91, 1053-1064
16. Yoshida, K.; Maeda, K.; Sugiyama, Y. Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms Annu. Rev. Pharmacol. Toxicol. 2013, 53, 581-612
17. Di, L.; Artursson, P.; Avdeef, A.; Ecker, G. F.; Faller, B.; Fischer, H.; Houston, J. B.; Kansy, M.; Kerns, E. H.; Kramer, S. D.; Lennernas, H.; Sugano, K. Evidence-based approach to assess passive diffusion and carrier-mediated drug transport Drug Discovery Today 2012, 17, 905-912
18. Higaki, K.; Choe, S. Y.; Lobenberg, R.; Welage, L. S.; Amidon, G. L. Mechanistic understanding of time-dependent oral absorption based on gastric motor activity in humans Eur. J. Pharm. Biopharm. 2008, 70, 313-325
19. Nimmo, W. S.; Heading, R. C.; Wilson, J.; Tothill, P.; Prescott, L. F. Inhibition of gastric emptying and drug absorption by narcotic analgesics Br. J. Clin. Pharmacol. 1975, 2, 509-513
20. Nimmo, W. S.; Littlewood, D. G.; Scott, D. B.; Prescott, L. F. Gastric emptying following hysterectomy with extradural analgesia Br. J. Anaesth. 1978, 50, 559-561
21. Nimmo, W. S.; Wilson, J.; Prescott, L. F. Narcotic analgesics and delayed gastric emptying during labour Lancet 1975, 1, 890-893
22. Di Bartolomeo, A. E.; Chapman, M. J.; Zaknic, V. A.; Summers, M. J.; Jones, K. L.; Nguyen, N. Q.; Rayner, C. K.; Horowitz, M.; Deane, A. M. Comparative effects on glucose absorption of intragastric and post-pyloric nutrient delivery in the critically ill Crit. Care 2012, 16, R167
23. Sellers, E. M.; Holloway, M. R. Drug kinetics and alcohol ingestion Clin. Pharmacokinet. 1978, 3, 440-452
24. Yamashita, S.; Kataoka, M.; Higashino, H.; Sakuma, S.; Sakamoto, T.; Uchimaru, H.; Tsukikawa, H.; Shiramoto, M.; Uchiyama, H.; Tachiki, H.; Irie, S. Measurement of drug concentration in the stomach after intragastric administration of drug solution to healthy volunteers: analysis of intragastric fluid dynamics and drug absorption Pharm. Res. 2013, 30, 951-958
25. Winiwarter, S.; Bonham, N. M.; Ax, F.; Hallberg, A.; Lennernas, H.; Karlen, A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach J. Med. Chem. 1998, 41, 4939-4949
26. Lennernas, H.; Nilsson, D.; Aquilonius, S. M.; Ahrenstedt, O.; Knutson, L.; Paalzow, L. K. The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man Br. J. Clin. Pharmacol. 1993, 35, 243-250
27. Nilsson, D.; Fagerholm, U.; Lennernas, H. The influence of net water absorption on the permeability of antipyrine and levodopa in the human jejunum Pharm. Res. 1994, 11, 1540-1547
28. Nyholm, D.; Lennernas, H.; Gomes-Trolin, C.; Aquilonius, S. M. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations Clin. Neuropharmacol. 2002, 25, 89-96
29. Nyholm, D.; Johansson, A.; Lennernas, H.; Askmark, H. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial Eur. J. Neurol. 2012, 19, 820-826
30. Nyholm, D.; Askmark, H.; Gomes-Trolin, C.; Knutson, T.; Lennernas, H.; Nystrom, C.; Aquilonius, S. M. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets Clin. Neuropharmacol. 2003, 26, 156-163
31. Langguth, P.; Lee, K. M.; Spahn-Langguth, H.; Amidon, G. L. Variable gastric emptying and discontinuities in drug absorption profiles: dependence of rates and extent of cimetidine absorption on motility phase and pH Biopharm. Drug Dispos. 1994, 15, 719-746
32. Koziolek, M.; Garbacz, G.; Neumann, M.; Weitschies, W. Simulating the postprandial stomach: biorelevant test methods for the estimation of intragastric drug dissolution Mol. Pharmaceutics 2013, 10, 2211-2221
33. Koziolek, M.; Garbacz, G.; Neumann, M.; Weitschies, W. Simulating the postprandial stomach: physiological considerations for dissolution and release testing Mol. Pharmaceutics 2013, 10, 1610-1622
34. Nyholm, D.; Lennernas, H.; Johansson, A.; Estrada, M.; Aquilonius, S. M. Circadian rhythmicity in levodopa pharmacokinetics in patients with Parkinson disease Clin. Neuropharmacol. 2010, 33, 181-185
35. Drescher, S.; Glaeser, H.; Murdter, T.; Hitzl, M.; Eichelbaum, M.; Fromm, M. F. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans Clin. Pharmacol. Ther. 2003, 73, 223-231
36. von Richter, O.; Greiner, B.; Fromm, M. F.; Fraser, R.; Omari, T.; Barclay, M. L.; Dent, J.; Somogyi, A. A.; Eichelbaum, M. Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique Clin. Pharmacol. Ther. 2001, 70, 217-227
37. Igel, S.; Drescher, S.; Murdter, T.; Hofmann, U.; Heinkele, G.; Tegude, H.; Glaeser, H.; Brenner, S. S.; Somogyi, A. A.; Omari, T.; Schafer, C.; Eichelbaum, M.; Fromm, M. F. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux Clin. Pharmacokinet. 2007, 46, 777-785
38. Fagerholm, U.; Nilsson, D.; Knutson, L.; Lennernas, H. Jejunal permeability in humans in vivo and rats in situ: investigation of molecular size selectivity and solvent drag Acta Physiol. Scand. 1999, 165, 315-324
39. Knutson, T.; Fridblom, P.; Ahlstrom, H.; Magnusson, A.; Tannergren, C.; Lennernas, H. Increased Understanding of Intestinal Drug Permeability Determined by the LOC-I-GUT Approach Using Multislice Computed Tomography Mol. Pharmaceutics 2009, 6, 2-10
40. Rambaud, J. C.; Modigliani, R.; Bernier, J. J. The method of intraluminal perfusion of the human small intestine. 3. Absorption studies in disease Digestion 1973, 9, 343-356
41. Modigliani, R.; Bernier, J. J. Absorption of glucose, sodium, and water by the human jejunum studied by intestinal perfusion with a proximal occluding balloon and at variable flow rates Gut 1971, 12, 184-193
42. Modigliani, R.; Rambaud, J. C.; Bernier, J. J. The method of intraluminal perfusion of the human small intestine. II. Absorption studies in health Digestion 1973, 9, 264-290
43. Modigliani, R.; Rambaud, J. C.; Bernier, J. J. The method of intraluminal perfusion of the human small intestine. I. Principle and technique Digestion 1973, 9, 176-192
44. Modigliani, R.; Rambaud, J. C.; Bernier, J. J. Validation of the use of a tube with a proximal occlusive balloon for measurement of intestinal absorption in man Am. J. Dig. Dis. 1978, 23, 720-722
45. Lennernas, H. Intestinal permeability and its relevance for absorption and elimination Xenobiotica 2007, 37, 1015-1051
46. Lennernas, H. Human intestinal permeability J. Pharm. Sci. 1998, 87, 403-410
47. Lennernas, H.; Ahrenstedt, O.; Hallgren, R.; Knutson, L.; Ryde, M.; Paalzow, L. K. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man Pharm. Res. 1992, 9, 1243-1251
48. Lennernas, H.; Ahrenstedt, O.; Ungell, A. L. Intestinal drug absorption during induced net water absorption in man; a mechanistic study using antipyrine, atenolol and enalaprilat Br. J. Clin. Pharmacol. 1994, 37, 589-596
49. Lennernas, H.; Fagerholm, U.; Raab, Y.; Gerdin, B.; Hallgren, R. Regional rectal perfusion: a new in vivo approach to study rectal drug absorption in man Pharm. Res. 1995, 12, 426-432
50. Lennernas, H.; Gjellan, K.; Hallgren, R.; Graffner, C. The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans J. Pharm. Pharmacol. 2002, 54, 499-508
51. Lennernas, H.; Knutson, L.; Knutson, T.; Hussain, A.; Lesko, L.; Salmonson, T.; Amidon, G. L. The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique Eur. J. Pharm. Sci. 2002, 15, 271-277
52. Lennernas, H. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans Curr. Drug Metab. 2007, 8, 645-657
53. Fagerholm, U.; Johansson, M.; Lennernas, H. Comparison between permeability coefficients in rat and human jejunum Pharm. Res. 1996, 13, 1336-1342
54. Lennernas, H.; Nylander, S.; Ungell, A. L. Jejunal permeability: a comparison between the ussing chamber technique and the single-pass perfusion in humans Pharm. Res. 1997, 14, 667-671
55. Tannergren, C.; Knutson, T.; Knutson, L.; Lennernas, H. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique Br. J. Clin. Pharmacol. 2003, 55, 182-190
56. Tannergren, C.; Engman, H.; Knutson, L.; Hedeland, M.; Bondesson, U.; Lennernas, H. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism Clin. Pharmacol. Ther. 2004, 75, 298-309
57. Sandstrom, R.; Knutson, T. W.; Knutson, L.; Jansson, B.; Lennernas, H. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans Br. J. Clin. Pharmacol. 1999, 48, 180-189
58. Sinko, P. J.; Leesman, G. D.; Amidon, G. L. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach Pharm. Res. 1991, 8, 979-988
59. Lennernas, H.; Lee, I. D.; Fagerholm, U.; Amidon, G. L. A residence-time distribution analysis of the hydrodynamics within the intestine in man during a regional single-pass perfusion with Loc-I-Gut: in-vivo permeability estimation J. Pharm. Pharmacol. 1997, 49, 682-686
60. Amidon, G. L.; Kou, J.; Elliott, R. L.; Lightfoot, E. N. Analysis of models for determining intestinal wall permeabilities J. Pharm. Sci. 1980, 69, 1369-1373
61. Fagerholm, U.; Lennernas, H. Experimental Estimation of the Effective Unstirred Water Layer Thickness in the Human Jejunum, and Its Importance in Oral-Drug Absorption Eur. J. Pharm. Sci. 1995, 3, 247-253
62. Borgstrom, B.; Dahlqvist, A.; Lundh, G.; Sjovall, J. Studies of intestinal digestion and absorption in the human J. Clin. Invest. 1957, 36, 1521-1536
63. Johnsson, G.; Regardh, C. G. Bioavailability of beta-adrenoceptor blocking drugs Br. J. Clin. Pharmacol. 1976, 3, 1064-1065 and author reply on p 1066
64. Johnsson, G.; Regardh, C. G. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs Clin. Pharmacokinet. 1976, 1, 233-263
65. Fagerholm, U.; Borgstrom, L.; Ahrenstedt, O.; Lennernas, H. The lack of effect of induced net fluid absorption on the in vivo permeability of terbutaline in the human jejunum J. Drug Target. 1995, 3, 191-200
66. Ming, X.; Knight, B. M.; Thakker, D. R. Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters Mol. Pharmaceutics 2011, 8, 1677-1686
67. Cvetkovic, M.; Leake, B.; Fromm, M. F.; Wilkinson, G. R.; Kim, R. B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine Drug Metab. Dispos. 1999, 27, 866-871
68. Petri, N.; Bergman, E.; Forsell, P.; Hedeland, M.; Bondesson, U.; Knutson, L.; Lennernas, H. First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model Drug Metab. Dispos. 2006, 34, 1182-1189
69. Petri, N.; Borga, O.; Nyberg, L.; Hedeland, M.; Bondesson, U.; Lennernas, H. Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers Int. J. Clin. Pharmacol. Ther. 2006, 44, 71-79
70. Lappin, G.; Shishikura, Y.; Jochemsen, R.; Weaver, R. J.; Gesson, C.; Houston, B.; Oosterhuis, B.; Bjerrum, O. J.; Rowland, M.; Garner, C. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability Eur. J. Pharm. Sci. 2010, 40, 125-131
71. Tannergren, C.; Petri, N.; Knutson, L.; Hedeland, M.; Bondesson, U.; Lennernas, H. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine Clin. Pharmacol. Ther. 2003, 74, 423-436
72. Yamazaki, A.; Kumagai, Y.; Yamane, N.; Tozuka, Z.; Sugiyama, Y.; Fujita, T.; Yokota, S.; Maeda, M. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS J. Clin. Pharm. Ther. 2010, 35, 169-175
73. Petri, N.; Tannergren, C.; Rungstad, D.; Lennernas, H. Transport characteristics of fexofenadine in the Caco-2 cell model Pharm. Res. 2004, 21, 1398-1404
74. Lennernas, H.; Palm, K.; Fagerholm, U.; Artursson, P. Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo Int. J. Pharmaceutics 1996, 127, 103-107
75. Kortejarvi, H.; Shawahna, R.; Koski, A.; Malkki, J.; Ojala, K.; Yliperttula, M. Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs J. Pharm. Sci. 2010, 99, 621-625
76. Kortejarvi, H.; Urtti, A.; Yliperttula, M. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates Eur. J. Pharm. Sci. 2007, 30, 155-166
77. Bonlokke, L.; Hovgaard, L.; Kristensen, H. G.; Knutson, L.; Lennernas, H. Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut) in humans Eur. J. Pharm. Sci. 2001, 12, 239-250
78. Bonlokke, L.; Hovgaard, L.; Kristensen, H. G.; Knutson, L.; Lindahl, A.; Lennernas, H. A comparison between direct determination of in vivo dissolution and the deconvolution technique in humans Eur. J. Pharm. Sci. 1999, 8, 19-27
79. Bonlokke, L.; Christensen, F. N.; Knutson, L.; Kristensen, H. G.; Lennernas, H. A new approach for direct in vivo dissolution studies of poorly soluble drugs Pharm. Res. 1997, 14, 1490-1492
80. Miller, J. M.; Beig, A.; Krieg, B. J.; Carr, R. A.; Borchardt, T. B.; Amidon, G. E.; Amidon, G. L.; Dahan, A. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation Mol. Pharmaceutics 2011, 8, 1848-1856
81. Xia, B.; Heimbach, T.; He, H.; Lin, T. H. Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability Biopharm. Drug Dispos. 2012, 33, 536-549
82. Budha, N. R.; Frymoyer, A.; Smelick, G. S.; Jin, J. Y.; Yago, M. R.; Dresser, M. J.; Holden, S. N.; Benet, L. Z.; Ware, J. A. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin. Pharmacol. Ther. 2012, 92, 203-213
83. Dahan, A.; Miller, J. M.; Hilfinger, J. M.; Yamashita, S.; Yu, L. X.; Lennernas, H.; Amidon, G. L. High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations Mol. Pharmaceutics 2010, 7, 1827-1834
84. Buckley, S. T.; Fischer, S. M.; Fricker, G.; Brandl, M. In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives Eur. J. Pharm. Sci. 2012, 45, 235-250
85. Sun, D.; Lennernas, H.; Welage, L. S.; Barnett, J. L.; Landowski, C. P.; Foster, D.; Fleisher, D.; Lee, K. D.; Amidon, G. L. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs Pharm. Res. 2002, 19, 1400-1416
86. Benet, L. Z.; Larregieu, C. A. The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted Clin. Pharmacol. Ther. 2010, 88, 405-407
87. Larregieu, C. A.; Benet, L. Z. Drug Discovery and Regulatory Considerations for Improving In Silico and In Vitro Predictions that Use Caco-2 as a Surrogate for Human Intestinal Permeability Measurements AAPS J. 2013, 15, 483-497
88. Lennernas, H. Animal data: the contributions of the Ussing Chamber and perfusion systems to predicting human oral drug delivery in vivo Adv. Drug Delivery Rev. 2007, 59, 1103-1120
89. Gramatte, T. Griseofulvin absorption from different sites in the human small intestine Biopharm. Drug Dispos. 1994, 15, 747-759
90. Gramatte, T.; Richter, K. Paracetamol absorption from different sites in the human small intestine Br. J. Clin. Pharmacol. 1994, 37, 608-611
91. Gramatte, T.; el Desoky, E.; Klotz, U. Site-dependent small intestinal absorption of ranitidine Eur. J. Clin. Pharmacol. 1994, 46, 253-259
92. Gramatte, T.; Oertel, R.; Terhaag, B.; Kirch, W. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans Clin. Pharmacol. Ther. 1996, 59, 541-549
93. Schedl, H. P. Absorption of steroid hormones from the human small intestine J. Clin. Endocrinol. Metab. 1965, 25, 1309-1316
94. Schedl, H. P.; Pierce, C. E.; Rider, A.; Clifton, J. A. Absorption of L-methionine from the human small intestine J. Clin. Invest. 1968, 47, 417-425
95. Schedl, H. P.; Clifton, J. A. Solute and Water Absorption by the Human Small Intestine Nature 1963, 199, 1264-1267
96. Lindahl, A.; Sandstrom, R.; Ungell, A. L.; Lennernas, H. Concentration- and region-dependent intestinal permeability of fluvastatin in the rat J. Pharm. Pharmacol. 1998, 50, 737-744
97. Fisher, R. B.; Parsons, D. S. The gradient of mucosal surface area in the small intestine of the rat J. Anat. 1950, 84, 272-282
98. Berggren, S.; Lennernas, P.; Ekelund, M.; Westrom, B.; Hoogstraate, J.; Lennernas, H. Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine J. Pharm. Pharmacol. 2003, 55, 963-972
99. Sjoberg, A.; Lutz, M.; Tannergren, C.; Wingolf, C.; Borde, A.; Ungell, A. L. Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique Eur. J. Pharm. Sci. 2013, 48, 166-180
100. Petri, N.; Tannergren, C.; Holst, B.; Mellon, F. A.; Bao, Y.; Plumb, G. W.; Bacon, J.; O'Leary, K. A.; Kroon, P. A.; Knutson, L.; Forsell, P.; Eriksson, T.; Lennernas, H.; Williamson, G. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo Drug Metab. Dispos. 2003, 31, 805-813
101. Johannsson, G.; Bergthorsdottir, R.; Nilsson, A. G.; Lennernas, H.; Hedner, T.; Skrtic, S. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study Eur. J. Endocrinol. 2009, 161, 119-130
102. Johannsson, G.; Nilsson, A. G.; Bergthorsdottir, R.; Burman, P.; Dahlqvist, P.; Ekman, B.; Engstrom, B. E.; Olsson, T.; Ragnarsson, O.; Ryberg, M.; Wahlberg, J.; Biller, B. M.; Monson, J. P.; Stewart, P. M.; Lennernas, H.; Skrtic, S. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation J. Clin. Endocrinol. Metab. 2012, 97, 473-481
103. Corrigan, O. I. The biopharmaceutic drug classification and drugs administered in extended release (ER) formulations Adv. Exp. Med. Biol. 1997, 423, 111-128
104. Schiller, C.; Frohlich, C. P.; Giessmann, T.; Siegmund, W.; Monnikes, H.; Hosten, N.; Weitschies, W. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging Aliment. Pharmacol. Ther. 2005, 22, 971-979
105. Sutton, S. C.; Evans, L. A.; Fortner, J. H.; McCarthy, J. M.; Sweeney, K. Dog colonoscopy model for predicting human colon absorption Pharm. Res. 2006, 23, 1554-1563
106. Thombre, A. G. Assessment of the feasibility of oral controlled release in an exploratory development setting Drug Discovery Today 2005, 10, 1159-1166
107. Wilding, I. Site-specific drug delivery in the gastrointestinal tract Crit. Rev. Ther. Drug Carrier Syst. 2000, 17, 557-620
108. Yang, L. Biorelevant dissolution testing of colon-specific delivery systems activated by colonic microflora J. Controlled Release 2008, 125, 77-86
109. Fagerholm, U.; Lindahl, A.; Lennernas, H. Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms J. Pharm. Pharmacol. 1997, 49, 687-690
110. Wilding, I. R. Evolution of the biopharmaceutics classification system (BCS) to oral modified release (MR) formulations; what do we need to consider? Eur. J. Pharm. Sci. 1999, 8, 157-159
111. Ammon, H. V.; Phillips, S. F. Inhibition of colonic water and electrolyte absorption by fatty acids in man Gastroenterology 1973, 65, 744-749
112. Devroede, G. J.; Phillips, S. F. Studies of the perfusion technique for colonic absorption Gastroenterology 1969, 56, 92-100
113. Billich, C. O.; Levitan, R. Effects of sodium concentration and osmolality on water and electrolyte absorption form the intact human colon J. Clin. Invest. 1969, 48, 1336-1347
114. Zimmermann, C.; Gutmann, H.; Hruz, P.; Gutzwiller, J. P.; Beglinger, C.; Drewe, J. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract Drug Metab. Dispos. 2005, 33, 219-224
115. Thorn, M.; Finnstrom, N.; Lundgren, S.; Rane, A.; Loof, L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract Br. J. Clin. Pharmacol. 2005, 60, 54-60
116. Seithel, A.; Karlsson, J.; Hilgendorf, C.; Bjorquist, A.; Ungell, A. L. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells Eur. J. Pharm. Sci. 2006, 28, 291-299
117. Raoof, A.; Moriarty, D.; Brayden, D.; Corrigan, O. I.; Cumming, I.; Butler, J.; Devane, J. Comparison of methodologies for evaluating regional intestinal permeability Adv. Exp. Med. Biol. 1997, 423, 181-189
118. Meier, Y.; Eloranta, J. J.; Darimont, J.; Ismair, M. G.; Hiller, C.; Fried, M.; Kullak-Ublick, G. A.; Vavricka, S. R. Regional distribution of solute carrier mRNA expression along the human intestinal tract Drug Metab. Dispos. 2007, 35, 590-594
119. Hilgendorf, C.; Ahlin, G.; Seithel, A.; Artursson, P.; Ungell, A. L.; Karlsson, J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines Drug Metab. Dispos. 2007, 35, 1333-1340
120. Englund, G.; Rorsman, F.; Ronnblom, A.; Karlbom, U.; Lazorova, L.; Grasjo, J.; Kindmark, A.; Artursson, P. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells Eur. J. Pharm. Sci. 2006, 29, 269-277